Literature DB >> 18356205

Cardiac resynchronization therapy in patients with heart failure and atrial fibrillation: importance of new-onset atrial fibrillation and total atrial conduction time.

Sandra Buck1, Michiel Rienstra, Alexander H Maass, Wybe Nieuwland, Dirk J Van Veldhuisen, Isabelle C Van Gelder.   

Abstract

AIMS: Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart failure and sinus rhythm (SR), but its value in atrial fibrillation (AF) remains unclear. Furthermore, response to CRT may be difficult to predict in these patients. The aim of our study was to investigate whether predictors for CRT success differ between patients with AF and SR and to study the influence of present or developing AF on response to CRT. METHODS AND
RESULTS: We examined consecutive patients in whom CRT was implanted disregarding the atrial rhythm. Atrial fibrillation was defined as either current or earlier AF, response to CRT was defined as a decrease in the left ventricular end-systolic volume of > or = 10% after 6 months. Total atrial conduction time (TACT), a measure to predict the risk of developing AF, was determined by echocardiography. We included 114 patients, of whom 56 (49%) were known with AF (23 current AF and 33 earlier AF). The other 58 patients had no history of AF. After 6 months, response in current and earlier AF and that in SR patients was comparable (56, 58 and 55%, respectively). In AF patients, multivariate analysis revealed a shorter TACT at baseline [odds ratio (OR) 16.7 (1.5-185.3), P = 0.02] and an interventricular mechanical delay (IVMD) > 40 ms [OR 10.4 (1.0-110.9), P = 0.05] as predictors for response. Non-responders more frequently suffered from new-onset AF (P = 0.02).
CONCLUSION: Failure to CRT is associated with new-onset AF. Total atrial activation time may be a parameter to predict response in AF patients.

Entities:  

Mesh:

Year:  2008        PMID: 18356205     DOI: 10.1093/europace/eun064

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  11 in total

1.  Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?

Authors:  Lucie Riedlbauchová; Václav Durdil; Jakub Honěk; Josef Veselka
Journal:  Int J Angiol       Date:  2020-04-28

2.  Cardiac resynchronisation therapy and the role of optimal device utilisation.

Authors:  S Buck; A H Maass; D J van Veldhuisen; I C Van Gelder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

3.  Phantom shocks: innocent bystander or complication of implantable cardioverter defibrillator therapy?

Authors:  A H Maass
Journal:  Neth Heart J       Date:  2013-04       Impact factor: 2.380

Review 4.  Cardiac Resynchronization Therapy in Patients with Atrial Fibrillation - Worth the Effort?

Authors:  António M Ferreira; Pedro Carmo; Pedro Adragão
Journal:  J Atr Fibrillation       Date:  2012-04-14

5.  Cardiac gene expression profiling - the quest for an atrium-specific biomarker.

Authors:  A H Maass; A-M R De Jong; M D Smit; L Gouweleeuw; R A de Boer; W H Van Gilst; I C Van Gelder
Journal:  Neth Heart J       Date:  2010-12       Impact factor: 2.380

6.  Interatrial conduction time and left atrial function in patients with left ventricular systolic dysfunction: effects of cardiac resynchronization therapy.

Authors:  Alan D Waggoner; Sujith Kalathiveetil; Karen E Spence; Víctor G Dávila-Román; Lisa de las Fuentes
Journal:  J Am Soc Echocardiogr       Date:  2009-04-02       Impact factor: 5.251

7.  Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial.

Authors:  Giovanni Luca Botto; Giuseppe Boriani; Stefano Favale; Maurizio Landolina; Giulio Molon; Claudio Tondo; Mauro Biffi; Giuseppe Grandinetti; Paolo De Filippo; Giovanni Raciti; Luigi Padeletti
Journal:  Trials       Date:  2011-02-15       Impact factor: 2.279

8.  Cardiac resynchronization in mild heart failure: all issues resolved? Editorial to "Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials" by Ronghui Tu et al.

Authors:  Alexander H Maass
Journal:  Cardiovasc Drugs Ther       Date:  2011-08       Impact factor: 3.727

9.  Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink).

Authors:  Johannes Brachmann; Michael Böhm; Karin Rybak; Gunnar Klein; Christian Butter; Hanno Klemm; Rolf Schomburg; Johannes Siebermair; Carsten Israel; Anil-Martin Sinha; Helmut Drexler
Journal:  Eur J Heart Fail       Date:  2011-05-08       Impact factor: 15.534

10.  Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta-analysis of observational studies.

Authors:  Usman Mustafa; Jessica Atkins; George Mina; Desiree Dawson; Catherine Vanchiere; Narendra Duddyala; Ryan Jones; Pratap Reddy; Paari Dominic
Journal:  Open Heart       Date:  2019-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.